ACW
Pharmaceuticals, Biotechnology & Life Sciences
Actinogen Medical
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 9 Oct 2026
- Reported shorts
- 15.9K
- Shares on issue
- 3.874B
Actinogen Medical (ACW) company profile
Profile, insiders and operations
Company
AI-generated research profile of Actinogen Medical
biotechnology
alzheimers treatment
neuroscience
pharmaceuticals
clinical trials
Actinogen Medical Limited focuses on the development and commercialization of novel therapeutic compounds, specifically targeting central nervous system diseases. Positioned as an innovative player in the biotechnology sector, Actinogen's flagship product, Xanamem, aims to treat Alzheimer's Disease and other neurodegenerative conditions, offering a unique therapeutic approach in a growing market. Their commitment to addressing unmet medical needs through rigorous clinical trials sets them apart from traditional pharmaceutical providers.
Director trades
20 trades recorded
ACW intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required